March 22, 2024 Ashling Wahner Newer-generation JAK inhibitors are increasingly adept at controlling symptoms in patients with myelofibrosis and may recapture treatment response in patients who have progressed on prior ruxolitinib (Jakafi), according to Joseph G. Jurcic, MD. “Using drugs that target all these particular abnormalities can result in symptom and spleen improvement, and in […]
March 22, 2024 By Laura Joszt, MA Interferons have been used for decades to treat myeloproliferative neoplasms (MPNs), and new emerging therapies, such as the Janus kinase (JAK) inhibitor ruxolitinib, are expanding the therapeutic armamentarium, said Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center. What is the importance of interferons as […]
El Bitar S 1, Arcasoy MO 1 Abstract The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxolitinib, and more recently, a novel recombinant interferon alfa-2 (IFN-α) therapeutic agent. Many clinical trials have documented the safety […]
Luis E. Aguirre, Akriti Jain, Somedeb Ball, Najla Al Ali, Virginia O. Volpe, Sara Tinsley-Vance, David Sallman, Kendra Sweet, Jeffrey Lancet, Eric Padrom, Seongseok Yun, Andrew Kuykendall, Rami Komrokji Abstract Background Myelofibrosis is the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms. About 90% of cases are driven by constitutive activation of 1 of 3 genes […]
Garima Pandey 1, Lucia Mazzacurati 1, Tegan M Rowsell 1, Nathan P Horvat 2, Narmin E Amin 1, Guolin Zhang 3, Afua A Akuffo 2, Christelle M Colin-Leitzinger 2, Eric B Haura 3, Andrew T Kuykendall 4, Ling Zhang 5, Pearlie K Epling-Burnette 2, Gary W Reuther 1 4 Abstract Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic neoplasms driven by mutationally activated signaling by the JAK2 tyrosine kinase. Although JAK2 inhibitors can improve MPN […]
March 7, 2024 Jordyn Sava 2023 brought a wave of positive developments for patients with myeloproliferative neoplasms (MPNs), particularly myelofibrosis. According to Raajit K. Rampal, MD, PhD, one study of particular interest was the phase 3 MANIFEST-2 trial (NCT04603495) of ruxolitinib (Jakafi) with pelabresib (CPI-0610).1 This study, in addition to the TRANSFORM-1 trial (NCT04472598), showed […]
Published: Mar 06, 2024 Updated preclinical data will be presented from Ryvu’s synthetic lethality pipeline, including PRMT5 inhibitors in MTAP-Deficient cancers, WRN inhibitors for the treatment of microsatellite unstable (MSI-H) tumors, and Ryvu’s cutting-edge synthetic lethality platform based on primary cancer cells. Poster presentation to highlight the synergistic effects of RVU120 in combination with ruxolitinib […]
February 6, 2024 Jonathan Goodman, MPhil A study published in the Annals of Hematology has highlighted the characteristics of patients with post-essential thrombocythemia or post-polycythemia vera myelofibrosis (PET-MF and PPV-MF, respectively) treated during the ruxolitinib era. Although the characteristics of patients with primary MF are well-established, less research has evaluated real-world data from patients with PET-MF or […]
January 30, 2024 Courtney Flaherty Ruxolitinib (Jakafi)-based combinations continue to demonstrate promising ability to address splenomegaly and a signal toward improvement of tumor-related symptoms in myelofibrosis. As novel targets for development are unearthed and considered for evaluation in combination with standard JAK inhibition, the assessment of other meaningful end points is necessary to confirm the […]
January 29, 2024 Ariana Pelosci The European Commission granted marketing authorization to momelotinib (Omjjara) for patients with primary myelofibrosis who have disease-related splenomegaly or moderate to severe anemia, according to a press release from GSK.1 This indication also covers patients with post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis who are JAK inhibitor naïve […]